Data Integrity Inspections Go Global For Pharma
This article was originally published in SRA
Executive Summary
Data integrity inspections that have disrupted pharmaceutical exports from India to the US and Europe are spreading to exporters in China and other countries, as well as to domestic US and European manufacturers that may be unprepared for them.
You may also be interested in...
FDA Warning Letter Hits US Lab On Data Integrity, Password Sharing
Data integrity lapses raised in FDA warning letter to California analytical testing lab shows that such issues are not confined to Asia and that FDA will, in fact, challenge US facilities to show they are managing their quality data properly.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.